Aralik 2008
Helikobakter pilori (+) fonksiyonel dispepside 7 ve 14 günlük pantoprazol temelli üçlü kombinasyon tedavisinin eradikasyona ve eradikasyonun semptomlara olan etkinliginin degerlendirilmesi
The effectiveness of pantoprazole based triple therapy regimen for 7 and 14 day periods, on the eradication of Helicobacter pylori and effects of the eradication on dyspeptic symptoms in Helicobacter pylori (+) functional dyspepsia
- Ana Sayfa
- Sayılar
- Aralik 2008
- Helikobakter pilori (+) fonksiyonel dispepside 7 ve 14 günlük pantoprazol temelli üçlü kombinasyon tedavisinin eradikasyona ve eradikasyonun semptomla...
Özet
Giris ve Amaç: Fonksiyonel dispepside, Helikobakter pilori eradikasyonunun dispeptik semptomlar üzerine etkisi ile ilgili çeliskili sonuçlar ortaya konmustur. Bu çalisma Helikobakter pilori enfeksiyonuna sahip, Roma II Fonksiyonel Dispepsi Kriterleri’ne uyan hastalarda; pantoprazol + klaritromisin + amoksisilin, üçlü tedavi rejiminin 7 ve 14 gün sürelerle verilmesi sonrasi, bu rejimin eradikasyondaki etkinliginin ve eradikasyonun dispeptik semptomlar üzerine etkisinin degerlendirilmesi amaciyla yapildi. Gereç ve Yöntem: Çalismaya toplam 93 hasta dahil edildi. Bu hastalardan 45’ine 7 gün, 48’ine de 14 gün süreyle belirlenen tedavi rejimi verildi. Hastalarin dispeptik semptomlari, Modifiye Glasgow Dispepsi Ciddiyet Skorlamasi kullanilarak skorlandi. Her iki tedavi grubunda eradikasyon, tedavi bitiminden 1 ay sonra, 13C üre nefes testi ile degerlendirildi. Tedavi sonrasi 1. hafta, 1. ay, 3. ay, 6. ay’da da ayni skorlama sistemi ile semptom skorlamalari tekrarlandi. Bulgular: Hem 7 günlük hem de 14 günlük tedavi, Helikobakter pilori eradikasyonunda basarili degildi. 7 günlük ve 14 günlük tedavilerin eradikasyon oranlari sirasiyla; %53.3 ve %70.8 (ITT analizlerine göre), %55.8 ve %75.6 (PP analizlerine göre) bulundu. Eradikasyon saglanan grupta, 6. ay sonunda dispepsi skoru “0” olan hasta orani, saglanamayan gruba göre istatistiksel olarak anlamli oranda yüksekti (sirasiyla %62.2’ye karsi %20 p<0.05). Sonuç: Bu çalismada kullanilan rejim, Helikobakter pilori eradikasyonunda basarili degildir. Fonksiyonel dispepsili hastalarda Helikobakter pilori enfeksiyonu saptandigi taktirde eradikasyon tedavisi verilmelidir.
Abstract
Background and Aims: The effects of Helicobacter pylori eradication therapy for dyspepsia symptoms in functional dyspepsia are conflicting. The aim of this study was to evaluate the effectiveness of pantoprazole + clarithromycin + amoxicillin triple therapy regimen for 7- and 14- day periods on the eradication of H. pylori and the effects of the eradication on the dyspeptic symptoms in patients with H. pylori infections and fulfilling Rome II Functional Dyspepsia Criteria. Materials and Methods: Ninety-three patients were included in this study. This triple therapy regimen was applied for 7 days to 45 patients, and for 14 days to 48 patients. Dyspeptic symptoms were scored according to the “Modified Version of the Glasgow Dyspepsia Severity Score Questionnaire”. Eradication was evaluated with 13C urea breath test, which was done one month after the end of the therapy in both groups. Scoring of dyspeptic symptoms were repeated one week later and 1, 3, and 6 months following the completion of treatments. Results: This therapy regimen was found unsuccessful for the eradication of the H. pylori with both 7- and 14-day applications. Eradication rates were 53.3% and 70.8%, respectively, according to ITT analysis; and 55.8% and 75.6%, respectively, according to PP analysis. Although the 6th month mean dyspepsia scores indicated a statistically significant decrease compared to baseline in the patient groups both with and without successful eradication, at the end of the 6th month, the rate of patients with “0” dyspepsia score was statistically significantly higher in the successful eradication group than in patients in whom eradication was not obtained (62.2% vs 20%, respectively, p<0.05). Conclusions: The regimen used in this study was not successful on H. pylori eradication. Eradication therapy must be applied in patients with functional dyspepsia who have H. pylori infection.
